Although SARS-CoV-2, the etiological agent for COVID-19, is initially and preferentially tropic for respiratory cellular targets3–5, its pathogenetic effects can be systemic. Indeed, dysregulated coagulopathy and systemic inflammation are hallmark characteristics of severe COVID-196,7, which involves acute respiratory distress syndrome (ARDS) as well as alterations of other organs8,9. The pathogenic mechanisms responsible for the most severe clinical progression of COVID-19 are yet poorly understood, although they appear to be multifactorial in nature. In this context, a relatively underexplored mechanistic pathway relates to autoimmunity. Autoantibodies that neutralize type-1 interferons have been described in severe adult COVID-1910, as have autoantibodies against self-antigens associated with systemic lupus erythematosus and Sjogren’s disease in severe pediatric COVID-1911. Additional reports of antiphospholipid autoantibodies have been associated with thrombotic events12,13 thereby linking immune dysregulation with thrombosis in severe COVID-1914. These observations underscore the urgent need to closely examine the intersection of immunopathology and severe COVID-19, particularly in pulmonary and vascular sites.
In this study, we first sought to detect auto-reactive antibodies in patient plasma using a comprehensive screening approach incorporating diverse and relevant cell types. Plasma samples were obtained from 64 patients hospitalized for COVID-19, including 55 patients with critical illness admitted to the intensive care unit (ICU; COVID ICU) and 9 patients with less severe disease admitted to the regular hospital floor (COVID non-ICU). Plasma was also obtained from 13 critically ill patients without SARS-CoV-2 infection (non-COVID ICU), 9 outpatients with hypergammaglobulinemia (Hyper-γ), and 12 healthy donors (Supplementary Table 1). Samples were screened for the presence of IgA, IgG, and IgM antibodies against 5 human cell types comprising of primary epithelial or endothelial cells of pulmonary, gut, or renal origin, as well as a highly utilized immortalized cell line with a pulmonary endothelial phenotype. Given that these cells have never been exposed to SARS-CoV-2 naïve, antibodies detected in this assay reflect the targeting of self-antigens and are not the consequence of reactivity against SARS-CoV-2 antigens.
Analysis of cells using conventional (Figure 1a) and imaging flow cytometry (Figure 1b-d) revealed the presence of antibodies binding to the plasma membrane. Scored against healthy and non-COVID controls, auto-reactive IgA, auto-reactive IgG and auto-reactive IgM were detected in 28 (51%), 23 (42%), and 51 (93%) out of 55 COVID ICU patients, respectively (Figure 1e). In each reaction, the percentage of cells that stained positively for IgM antibodies was far greater than IgA or IgG, suggesting higher circulating auto-reactive IgM titers. Although COVID ICU patients were associated with higher circulating interleukin-6 (IL-6) and C-reactive protein (CRP) (Supplementary Figure 1a-b), only auto-IgM levels were modestly associated with increased plasma interleukin-6 (IL-6) (⍴=0.29, p=0.0056; Supplementary Figure 2a-b). Of note, most COVID ICU patient plasma showed IgA, IgG, IgM, or a combination of, reactivity with cells of pulmonary origin (Figure 1f). Although a significant percentage of COVID ICU patients had detectable levels of auto-reactive IgA and IgG, we focused on auto-reactive IgM given its substantially higher titers and frequency. Overall, this first set of data revealed that high-titer auto-reactive IgM are frequently detected in patients with severe COVID-19 and that the reactivity is most pronounced against cells of pulmonary epithelial and endothelial origin.
We next sought to understand which auto-antigens are targeted by these circulating auto-reactive IgM in COVID-19 patients. Plasma samples from COVID ICU patients with strong auto-reactive IgM titers (n=5), non-COVID ICU patients (n=3) and healthy controls (n=4) were surveyed in analytical human proteome microarrays (HuProt v4 array). The array epxresses over 21,000 intact proteins, therefore allowing for a thorough and comprehensive investigation of potential binding targets for auto-reactive IgM antibodies. For stringency, a potential binding target was considered for any protein that had a fluorescence signal at least 4 standard deviations (Z-score>4) above the array mean. Additionally, the target had to possess a fluorescence signal at least 2 Z-scores above the same target across all healthy controls. This strict approach resulted in the identification of 260 candidate autoantigens that were uniquely linked to COVID ICU patients (Figure 2a and Supplementary Table 2). Of note, the auto-reactive IgM repertoire in COVID ICU patients is broad, and the candidate targets infrequently overlapped among different patients included in this cohort (Figure 2b). It is very likely, and anticipated, that interrogation of additional plasma samples from patients with severe COVID-19 by proteome microarray would identify further auto-antigen targets, and that the individual antigenic targets are likely less relevant to the disease pathogenesis than the overall abundance, breadth, and tissue specificity of the observed auto-antibodies.
Given the high Z-scores of each candidate target, the auto-reactive IgM antibodies are circulating at robust titers and/or bind with high avidity to the respective targets. We next sought to determine whether the candidate autoantigens were expressed in key tissue types. Using arterial tissues as surrogates for endothelial sites, small intestinal and colonic tissues as surrogates for gastrointestinal sites, as well as renal, neural, and pulmonary sites, we found 226 candidate autoantigens expressed at above-background levels in these cell types (Figure 2c). Importantly, we identified 16 autoantigens associated with the human plasma membrane proteome15 and therefore considered these molecules as important prospective candidate targets for circulating pathogenic auto-reactive IgM (Figure 2d). We next investigated whether these proteins shared similar motifs. Although N-linked glycosylation was predicted in 11 candidate autoantigens, heterogeneity in amino acid sequences flanking predicted N-linked glycosylated residues indicated minimal influence of N-linked glycosylation on potential IgM binding motifs (Supplementary Figure 3a). However, an artificial neural network prediction model16 revealed extensive O-linked glycosylation for 12 candidate autoantigens (Supplementary Figure 3b-c). Notably, these sites are enriched for proline and serine, which are signs of authentic glycosylation in regions likely to mediate protein-IgM interactions.
The concomitant observations of auto-reactive IgM potentially targeting O-linked glycosylated motifs and high expression of candidate autoantigens in pulmonary sites led us to hypothesize that auto-reactive IgM are a significant contributor to severe COVID-19 disease. To further explore the in vivo relationship between auto-reactive IgM and COVID-19 pathophysiology, we first examined post-mortem pulmonary tissue to determine IgM distribution and presence. Immunohistochemical staining of paraffin-embedded lung tissue revealed vastly greater IgM binding to alveolar septa and luminal surfaces of three COVID-19 non-survivors, compared to three COVID-19 negative control patients for whom lung tissue was available from cancer-related resection (Figure 3a). It should be noted that some modest IgM deposition in the COVID-19 negative patient controls was expected, as auto-reactive IgMs can develop during lung cancer progression17 and/or following radiation therapy18. While we cannot formally rule out that the IgM detected in COVID-19+ lung tissue are reactive against SARS-CoV-2 surface antigens, the observed staining patterns are not consistent with the distribution patterns observed for SARS-CoV-2 antigens such as the Spike protein19,20. Importantly, the extensive IgM staining patterns are at levels at least three times higher than COVID-19 negative controls (Figure 3b), and are not described for other causes of acute respiratory distress21. Further histological analysis revealed, in the lung of severe COVID-19 patients, significant alveolar damage and patchy hemorrhage, alongside extensive inflammatory infiltrate breaching the alveolar lumen. Previous studies have linked alveolar damage to dysregulated cytokine release and neutrophil extracellular traps seeded by resident macrophages22–25. Yet, these observations could also be linked to auto-reactive IgM, through the capacity of these immunoglobulins to fix complement and induce cytotoxicity. Indeed, staining for complement component 4 (C4d), a marker of complement activation, showed a two-fold increase in COVID-19 patients compared to negative controls (Figure 3c), indicating frequent in vivo complement fixation.
Complement-dependent cytotoxicity (CDC) and complement deregulation have been proposed to play a roles in the pathogenesis of ARDS26. Additionally, as there is considerable pulmonary microangiopathy observed in severe COVID-19 patients27,28, it is conceivable that CDC can precede or even cause the damage to the pulmonary endothelium. Given the observed IgM and C4d binding to pulmonary targets and to confirm that the auto-reactive IgM can mediate CDC, we next tested plasma samples from severe COVID-19 patients for their capability of fixing complement and inducing cytotoxicity in vitro. To this end, we investigated patient plasma samples that showed greater than 10% binding to the respective cell type in the screening assay. Interestingly, we consistently observed higher rates of CDC in cells of pulmonary origin (Figure 3d-h). In addition, while non-COVID-19 ICU patient plasma samples induced limited or no cell death, most COVID-19 ICU patients plasma samples induced cell death at frequencies proportional to their measured level of cell binding (Figure 3i). Collectively, these data indicate that auto-reactive IgM present in plasma from severe COVID-19 patients can fix complement and induce cytotoxicity.
The identification of auto-reactive IgM as a potential contributing factor to the pathogenesis of severe COVID-19 has two immediate implications. First, this observation may explain how COVID-19 is disproportionately more serious in the elderly29, who typically manifest higher plasma levels of circulating auto-reactive antibodies30. This phenomenon would be exacerbated by decreases in functional T follicular helper cells that promote antibody class switching31, a process associated with better disease outcomes32. Given that IgM levels peak within a week of the clinical onset of COVID-19 and persist at similar levels for weeks thereafter34, the elderly face a protracted period where there is steadfast secretion of auto-reactive IgM that maintain relatively low affinity for the same epitope without either switching to alternate antibody class types or undergoing somatic hypermutation and affinity maturation. In this perspective, the elderly may be more prone to severe COVID-19 due to a more protracted exposure to the cytopathic effects of auto-reactive IgM.
Secondly, it is conceivable that this type of immunopathology can be limited by therapeutic interventions that inhibit the IgM-complement axis. In the immediate term, this approach could mitigate the SARS-CoV-2 associated alveolar damage and ARDS35–37, and consequently protect against mortality38 and/or reduce the need for invasive mechanical ventilation39. In the long term, preservation of lung integrity may prevent pathogenic sequelae such as pulmonary fibrosis40,41, which diminishes lung function post-recovery42. These therapeutic goals could be implemented through the use of immunosuppressants, such as dexamethasone, that can attenuate the production of auto-reactive IgM 43, plasma exchange to remove auto-reactive IgM once formed44, or to synergize and supplement proposed anti-fibrotic therapies45. Alternatively, the complement cascade can be directly inhibited through conestat alfa46 or eculizumab46, and indeed, both drugs are presently undergoing evaluation through clinical trials to determine efficacy47. Optimistically, our findings cast support for interventions that can be readily and swiftly implemented in the clinic to alleviate or prevent serious COVID-19 complications.
In summary, we found that broadly auto-reactive IgM are common in the plasma of patients with severe COVID-19. These auto-reactive antibodies bind pulmonary epithelial and endothelial targets, at which point they can be potent mediators of cytopathicity through the recruitment of complement. Future studies will investigate the relationship between SARS-CoV-2 infection and the emergence of auto-reactive antibodies, and determine whether immunosuppressive therapy can reduce the levels of auto-reactive IgM in plasma and consequently attenuate the clinical severity of COVID-19.